gossypol has been researched along with Leukemia in 11 studies
Gossypol: A dimeric sesquiterpene found in cottonseed (GOSSYPIUM). The (-) isomer is active as a male contraceptive (CONTRACEPTIVE AGENTS, MALE) whereas toxic symptoms are associated with the (+) isomer.
Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gossypol treatment resulted in a decrease of c-Myc expression and binding activity." | 5.35 | Gossypol suppresses telomerase activity in human leukemia cells via regulating hTERT. ( Choi, YH; Kim, GY; Kim, MO; Kim, ND; Lee, HG; Moon, DO, 2008) |
| "Treatment with gossypol also downregulated expression of NF-kappaB-regulated gene products, including inhibitor of apoptosis protein (IAP)-1, IAP-2, and X-linked IAP." | 5.35 | Gossypol suppresses NF-kappaB activity and NF-kappaB-related gene expression in human leukemia U937 cells. ( Kim, GY; Kim, MO; Lee, JD; Moon, DO, 2008) |
| "Gossypol inhibited 5- and 12-lipoxygenases of rat basophilic leukemia (RBL-1) cells with ID50 of 0." | 3.67 | Gossypol, a potent inhibitor of arachidonate 5- and 12-lipoxygenases. ( Hamasaki, Y; Tai, HH, 1985) |
| "Gossypol treatment resulted in a decrease of c-Myc expression and binding activity." | 1.35 | Gossypol suppresses telomerase activity in human leukemia cells via regulating hTERT. ( Choi, YH; Kim, GY; Kim, MO; Kim, ND; Lee, HG; Moon, DO, 2008) |
| " Hepatotoxicity and gastrointestinal toxicity represented the major adverse activities of gossypol, with apogossypol far less toxic." | 1.35 | Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2-transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048). ( Jia, L; Kitada, S; Krajewska, M; Kress, CL; Pellecchia, M; Reed, JC, 2008) |
| "Treatment with gossypol also downregulated expression of NF-kappaB-regulated gene products, including inhibitor of apoptosis protein (IAP)-1, IAP-2, and X-linked IAP." | 1.35 | Gossypol suppresses NF-kappaB activity and NF-kappaB-related gene expression in human leukemia U937 cells. ( Kim, GY; Kim, MO; Lee, JD; Moon, DO, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (18.18) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Das, SG | 1 |
| Doshi, JM | 1 |
| Tian, D | 1 |
| Addo, SN | 1 |
| Srinivasan, B | 1 |
| Hermanson, DL | 1 |
| Xing, C | 1 |
| Vizirianakis, IS | 1 |
| Chatzopoulou, M | 1 |
| Bonovolias, ID | 1 |
| Nicolaou, I | 1 |
| Demopoulos, VJ | 1 |
| Tsiftsoglou, AS | 1 |
| Li, G | 1 |
| Liu, L | 1 |
| Shan, C | 1 |
| Cheng, Q | 1 |
| Budhraja, A | 1 |
| Zhou, T | 1 |
| Cui, H | 1 |
| Gao, N | 1 |
| Zhang, SD | 1 |
| Shan, L | 1 |
| Li, W | 1 |
| Li, HL | 1 |
| Zhang, WD | 1 |
| Moon, DO | 2 |
| Kim, MO | 2 |
| Choi, YH | 1 |
| Lee, HG | 1 |
| Kim, ND | 1 |
| Kim, GY | 2 |
| Goff, DJ | 1 |
| Court Recart, A | 1 |
| Sadarangani, A | 1 |
| Chun, HJ | 1 |
| Barrett, CL | 1 |
| Krajewska, M | 2 |
| Leu, H | 1 |
| Low-Marchelli, J | 1 |
| Ma, W | 1 |
| Shih, AY | 1 |
| Wei, J | 1 |
| Zhai, D | 1 |
| Geron, I | 1 |
| Pu, M | 1 |
| Bao, L | 1 |
| Chuang, R | 1 |
| Balaian, L | 1 |
| Gotlib, J | 1 |
| Minden, M | 1 |
| Martinelli, G | 1 |
| Rusert, J | 1 |
| Dao, KH | 1 |
| Shazand, K | 1 |
| Wentworth, P | 1 |
| Smith, KM | 1 |
| Jamieson, CA | 1 |
| Morris, SR | 1 |
| Messer, K | 1 |
| Goldstein, LS | 1 |
| Hudson, TJ | 1 |
| Marra, M | 1 |
| Frazer, KA | 1 |
| Pellecchia, M | 2 |
| Reed, JC | 2 |
| Jamieson, CH | 1 |
| Cleverley, J | 1 |
| Kitada, S | 1 |
| Kress, CL | 1 |
| Jia, L | 1 |
| Lee, JD | 1 |
| Hamasaki, Y | 2 |
| Miyazaki, S | 1 |
| Tai, HH | 2 |
1 review available for gossypol and Leukemia
| Article | Year |
|---|---|
Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Differentiation; Clinical Trials as Topic; Drug Eval | 2010 |
10 other studies available for gossypol and Leukemia
| Article | Year |
|---|---|
Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4h-chromene-3-carboxylate (sha 14-1) and its analogues.
Topics: Apoptosis; Benzopyrans; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Leukemia; | 2009 |
RhoA/ROCK/PTEN signaling is involved in AT-101-mediated apoptosis in human leukemia cells in vitro and in vivo.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Gossypol; Humans; Leuke | 2014 |
Isochamaejasmin induces apoptosis in leukemia cells through inhibiting Bcl-2 family proteins.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Biflavonoids; Caspase 3; C | 2015 |
Gossypol suppresses telomerase activity in human leukemia cells via regulating hTERT.
Topics: Active Transport, Cell Nucleus; Apoptosis; Cell Line, Tumor; Cell Proliferation; Contraceptive Agent | 2008 |
A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition.
Topics: Blast Crisis; Gossypol; Humans; Leukemia; Neoplastic Stem Cells; Protein Kinase Inhibitors; Proto-On | 2013 |
American Society of Clinical Oncology--42nd annual meeting. Poster presentations on leukemia and cytotoxic chemotherapy. 2-6 June 2006, Atlanta, GA, USA.
Topics: Clinical Trials as Topic; Cytarabine; Drug Combinations; Gossypol; Humans; Leukemia; Mastocytosis, S | 2006 |
Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2-transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048).
Topics: Animals; B-Lymphocytes; Cell Survival; Cells, Cultured; Female; Gossypol; Humans; Leukemia; Lymphoma | 2008 |
Gossypol suppresses NF-kappaB activity and NF-kappaB-related gene expression in human leukemia U937 cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Proliferation; Dose-Response Relationship, | 2008 |
[Rat basophilic leukemia-1 cell possesses 12-lipoxygenase and 5-lipoxygenase activities which are specifically inhibited by gossypol acetic acid].
Topics: Animals; Arachidonate Lipoxygenases; Basophils; Cells, Cultured; Gossypol; Hydroxyeicosatetraenoic A | 1984 |
Gossypol, a potent inhibitor of arachidonate 5- and 12-lipoxygenases.
Topics: Animals; Arachidonate Lipoxygenases; Arachidonic Acid; Arachidonic Acids; Basophils; Cyclooxygenase | 1985 |